RESUMO
Over the past few decades, many reports were published in scientific journals describing medicinal properties of Ficusglomerata (FG). However, its effects on embryonic development and its safety characteristics have not been studied.The purpose of this investigation was to determine lethal concentration 50 (LC50) and study the effect of aqueousextract of FG leaf (AEFG) on developmental abnormalities in zebrafish embryos. LC50 value of AEFG was calculatedby using probit analysis. Effect on percentage hatchability, heartbeat rate, total body length, and developmentalmorphological abnormalities, i.e., delayed growth, abnormal movement, tail detachment, abnormal head-trunkangle, scoliosis/flexure, and yolk sac edema were recorded. AEFG revealed LC50 of 239.88 ppm. The result showeda significant reduction in percent hatchability (p < 0.05), heartbeat rate (p < 0.001), total body length (p < 0.001),and developmental morphological abnormalities in the embryos treated with AEFG. This research can be used inconsidering the safety of an AEFG extract for their use during pre-conception or early pregnancy period.
RESUMO
The present work was carried out to study the disintegrant property of plantago ovata mucilage. The objective of the work was to formulate fast disintegrating tablets of Domperidon with a view to enhance patient compliances and dissolution rate by direct compression method using 3² full factorial design. Plantago ovata mucilage (2-10% w/w) was used as natural superdisintegrant and microcrystalline cellulose (0-30% w/w) was used as diluent, along with directly compressible mannitol to enhance mouth feel. The tablets were evaluated for hardness, friability, thickness, drug content uniformity, in vitro dispersion time, wetting time and water absorption ratio. Based on in vitro dispersion time (approximately 10s); the formulation containing 10% w/w Plantago ovata mucilage and 30%w/w microcrystalline cellulose was found to be promising and tested for in vitro drug release pattern (in 0.1 N HCl), short-term stability (at 40º/75% RH for 3 month) and drug-excipient interaction. Surface response plots are presented to graphically represent the effect of independent variables (concentrations of Plantago ovata mucilage and microcrystalline cellulose) on the in vitro dispersion time. The validity of the generated mathematical model was tested by preparing two extra-design check point formulations. The optimized tablet formulation was compared with conventional commercial tablet formulation for drug release profiles. This formulation showed nearly four-fold faster drug release (t50% 2.85 min) compared to the conventional commercial tablet formulation (t50% 7.85 min). Short-term stability studies on the formulation indicated that there are no significant changes in drug content and in vitro dispersion time (p < 0.05).
RESUMO
The present work was carried out to study the disintegrant property of plantago ovata mucilage. The objective of the work was to formulate Fast disintegrating tablets of Domperidon with a view to enhance patient compliances and dissolution rate by direct compression method using 3² full factorial design. Plantago ovata mucilage (2-10% w/w) was used as natural superdisintegrant and microcrystalline cellulose (0-30% w/w) was used as diluent, along with directly compressible mannitol to enhance mouth feel. The tablets were evaluated for hardness, friability, thickness, drug content uniformity, in vitro dispersion time, wetting time and water absorption ratio. Based on in vitro dispersion time (approximately 10s); the formulation containing 10% w/w Plantago ovata mucilage and 30%w/w microcrystalline cellulose was found to be promising and tested for in vitro drug release pattern (in 0.1 N HCl), short-term stability (at 40º/75% RH for 3 month) and drug-excipient interaction. Surface response plots are presented to graphically represent the effect of independent variables (concentrations of Plantago ovata mucilage and microcrystalline cellulose) on the in vitro dispersion time. The validity of the generated mathematical model was tested by preparing two extra-design check point formula-tions. The optimized tablet formulation was compared with conventional commercial tablet formulation for drug release profiles. This formulation showed nearly four-fold faster drug release (t50% 2.85 min) compared to the conventional commercial tablet formulation (t50% 7.85 min). Short-term stability studies on the formulation indicated that there are no significant changes in drug content and in vitro dispersion time (p < 0.05).